Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapsuleX and Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer
NCT07495384Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jan 2025
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of CapsuleX in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The First Hospital of Jilin University. Primary endpoint: Objective Response Rate at 5 years. Started Jan 2025; status: recruiting.
02
Drugs
CapsuleX
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07495384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495384.